Cipla vs Apollohosp Q1 FY24

Cipla delivered a strong Q1 FY24 with 18% YoY revenue growth to INR 6,329 crore, driven by record performance in India (12% growth) and the US ($222 million, +43% YoY). EBITDA margin expanded to 23.6%, aided by favorable mix and operational efficiencies. PAT stood at INR 996 crore (15.7% of sales). The US complex portfolio, including Lanreotide (18% market share) and stabilized Albuterol, powered growth, while India's chronic share rose to 60%. Management raised full-year EBITDA margin guidance to ~23% (from 22% earlier). Key pipeline catalysts include Symbicort filing by year-end, 4-5 peptide launches over two years, and de-risking of Advair and Abraxane. Risks include US FDA classification for Indore facility and potential pricing pressure in the US generics market.

Guidance read

Full-year EBITDA margin target of ~23%: Management raised FY24 EBITDA margin guidance to approximately 23%, up from earlier 22% guidance, driven by strong Q1 performance and confidence across markets. Symbicort filing by end of FY24: Cipla expects to file generic Symbicort (respiratory product) by the end of calendar year 2023. 4-5 peptide launches in next two years: Cipla plans to launch 4-5 peptide products over the next two years, with a couple of new peptide filings in the same period. Advair launch within 12 months via de-risking: Generic Advair is being transferred to an in-house facility; launch expected within 12 months with no incremental generic competition anticipated.

Risk read

Key risks include US FDA classification for Indore facility pending — Cipla awaits US FDA classification for its Indore facility, which was audited in February 2023. This could impact approvals for key products like generic Advair.; Albuterol recall and market share loss — Cipla faced an Albuterol recall in Q1 and experienced a market share decline in Q4 FY23, though management states share has stabilized.; Potential pricing pressure in US generics — While price erosion has eased, management noted it could revert to higher levels in later quarters, impacting US revenue sustainability.; Goa facility re-inspection uncertainty — Cipla's Goa facility is under remediation and expects re-inspection in H2 FY24. Any adverse outcome could disrupt supply of key products..

Promise ledger

Scorecard data is being built as historical quarters are processed.

Apollo Hospitals reported a solid Q1 FY24 with consolidated revenue of INR 4,418 crore (+16% YoY) and EBITDA of INR 509 crore (+4% YoY). Healthcare services grew 13% YoY, driven by a 6% increase in IP volumes and an 11% ARPOB improvement to INR 57,760. Insurance revenue mix improved to 44% of IP revenues. The pharmacy distribution business grew 24% YoY, while Apollo 24|7 GMV surged 189% YoY to INR 623 crore, with operating losses narrowing to INR 57 crore. Management reiterated guidance for Apollo 24|7 to achieve operational breakeven by Q4 FY24 and for combined pharmacy to reach INR 10,000 crore revenue with 6% EBITDA margins. Key risks include slower-than-expected occupancy ramp-up in new hospitals and margin pressure from investments in clinical talent and marketing.

Guidance read

Apollo 24|7 operational breakeven by Q4 FY24: Management reiterated that Apollo 24|7 is on track to achieve operational breakeven in Q4 FY24, with EBITDA loss narrowing to INR 57 crore in Q1. Combined pharmacy revenue target of INR 10,000 crore with 6% EBITDA margin: Management guided for combined pharmacy (offline + online) to reach INR 10,000 crore revenue and 6% EBITDA margins, with 500-600 new store additions planned for FY24. Occupancy target of 70% without additional CapEx: Management expects to reach 70% occupancy over time without requiring significant capital expenditure, leveraging existing capacity. Discount rationalization to 13-14% range for online pharmacy: Management guided that online pharmacy discounts will remain in the 13-14% range for the rest of FY24, with offline discounts at 12-12.5%.

Risk read

Key risks include Occupancy ramp-up slower than expected — Overall occupancy at 62% remains below the 70% target, with new hospitals at 60% and some regions like Tamil Nadu seeing muted volumes due to seasonal factors.; Margin pressure from new store additions and clinical investments — Combined pharmacy EBITDA margins are under pressure due to 20% of stores yet to reach breakeven, and new hospitals face margin drag from doctor hiring and marketing costs.; Apollo 24|7 GMV growth may be impacted by discount reduction — The decision to reduce discounts and filter low-value orders led to a sequential decline in pharmacy GMV, and achieving the INR 3,000 crore GMV target may be challenging.; Indraprastha Medical lease renewal uncertainty — Management deferred providing an update on the lease renewal for Indraprastha Medical, which could impact future operations and expansion plans..

Promise ledger

Scorecard data is being built as historical quarters are processed.